IN8bio
INAB
19 hedge funds and large institutions have $5.55M invested in IN8bio in 2026 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less funds holding
Funds holding: 22 → 19 (-3)
25% less capital invested
Capital invested by funds: $7.45M → $5.55M (-$1.9M)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
38.41% less ownership
Funds ownership: 76.52% → 38.11% (-38%)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$964K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$126K |
| 3 |
OC
Oppenheimer & Co
New York
|
+$46.5K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$29K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$5.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BIOS Capital Management
Fort Worth,
Texas
|
-$166K |
| 2 |
Two Sigma Investments
New York
|
-$66K |
| 3 |
HF
HRT Financial
New York
|
-$34K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$25.5K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$8.91K |
INAB Hedge Fund Activity: Q1 2026 in Review
19 of the 8,203 institutional investors tracked by Wall St. Rank reported a position in IN8bio (INAB) for Q1 2026, worth a combined $5.55M — down 25% from $7.45M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of INAB and 3 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Stonepine Capital Management, adding an estimated $964K. The largest seller was BIOS Capital Management, cutting an estimated $166K.
- 19 institutional investors held IN8bio (INAB) as of Q1 2026, down from 22 in Q4 2025.
- Funds reported $5.55M of IN8bio stock for Q1 2026, down 25% quarter-over-quarter.
- 3 funds opened new IN8bio positions in Q1 2026 and 5 closed out, a net change of -2 holders.
- The largest IN8bio buyer in Q1 2026 was Stonepine Capital Management, an estimated $964K added.
- The largest IN8bio seller in Q1 2026 was BIOS Capital Management, an estimated $166K sold.
Based on aggregated 13F filings for Q1 2026.